Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × olverembatinib × Clear all
NCT04126707 2021-09-08

The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans

Ascentage Pharma Group Inc.

Phase 1 Completed
6 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03882281 2020-01-22

CML

Ascentage Pharma Group Inc.

Phase 1 Completed
12 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡